A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

Dissemination and publication of research findings: an updated review of related biases

“…217 Further, in the year before the withdrawal, the authors of a systematic review had written directly to the primary author of every published trial of rofecoxib asking about cardiovascular events and major bleeds; however, they received only a single reply and it did not provide data on cardiovascular events. 218 In a more recent case study, Psaty and Kronmal (2008) found biased reporting of findings from clinical trials of rofecoxib for Alzheimer's disease or cognitive impairment. 219 Before its withdrawal, rofecoxib had been used in more than 80 million patients.…”

NSAIDs and Peptic Ulcer Disease

“…Recurrent symptomatic or bleeding ulcers (20% versus 0%) and gastrointestinal bleeding (7.7% versus 0%) were more common in patients on famotidine than in those on pantoprazole (Ng et al, 2010). However, economic modeling suggests that co-therapy with H2 receptor antagonists may be a cost-effective strategy for the prevention of ulcer bleeding in NSAID users (Brown et al, 2006). Like PPIs, there have not been any randomized, clinical outcome trials that evaluate the efficacy of H2 receptor antagonists in chronic NSAID users.…”

Severe Serum Sickness-Like Reaction: Challenges in Diagnosis and Management

“…These complications may occur within the first week of treatment [12]. In a recent meta-analysis it was reported that adding a proton pump inhibitor (but not a histamine-2 receptor antagonist) to treatment with NSAIDs will reduce the risk of symptomatic ulcers associated with NSAIDs treatment [13].…”